Taysha Gene Therapies’ (TSHA) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report sent to investors on Tuesday, Benzinga reports. Needham & Company LLC currently has a $7.00 price objective on the stock.

A number of other research firms also recently commented on TSHA. BMO Capital Markets assumed coverage on shares of Taysha Gene Therapies in a research note on Thursday, June 27th. They set an outperform rating and a $5.00 price objective for the company. Chardan Capital reaffirmed a buy rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, June 18th. Piper Sandler dropped their price objective on Taysha Gene Therapies from $9.00 to $7.00 and set an overweight rating on the stock in a research note on Monday, July 1st. Cantor Fitzgerald reissued an overweight rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Finally, Jefferies Financial Group reaffirmed a buy rating and issued a $8.00 price objective (up from $2.00) on shares of Taysha Gene Therapies in a research report on Tuesday, May 14th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $6.60.

Taysha Gene Therapies Trading Up 1.3 %

NASDAQ:TSHA opened at $2.27 on Tuesday. The company has a market cap of $424.54 million, a P/E ratio of -4.63 and a beta of 0.41. Taysha Gene Therapies has a twelve month low of $0.62 and a twelve month high of $4.32. The business has a 50 day moving average price of $2.87 and a two-hundred day moving average price of $2.49. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.75.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $3.41 million for the quarter, compared to analyst estimates of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. As a group, analysts expect that Taysha Gene Therapies will post -0.41 EPS for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning acquired 1,333,333 shares of Taysha Gene Therapies stock in a transaction on Thursday, June 27th. The shares were purchased at an average cost of $2.25 per share, for a total transaction of $2,999,999.25. Following the completion of the purchase, the insider now directly owns 1,333,333 shares of the company’s stock, valued at approximately $2,999,999.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 2.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors and hedge funds have recently added to or reduced their stakes in TSHA. ADAR1 Capital Management LLC acquired a new position in shares of Taysha Gene Therapies during the 4th quarter worth $370,000. Vanguard Group Inc. raised its stake in Taysha Gene Therapies by 235.2% during the third quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock worth $16,836,000 after acquiring an additional 3,738,616 shares in the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Taysha Gene Therapies by 11.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock worth $7,709,000 after acquiring an additional 430,555 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $38,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at approximately $28,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.